Inflammatory reactions contribute to the pathogenesis of cardiovascular conditions such as atherosclerosis and ischemic damage in acute myocardial infarction (AMI). Among the mediators involved in inflammation are secretory phospholipase A2 group II (sPLA2-II) enzymes. Though some cells constitutively express sPLA2-II, the synthesis by cells such as hepatocytes is typical for an acute-phase reactant. Recent literature suggests multiple roles for sPLA2-II in cardiovascular disease. In this review we discuss the role of sPLA2-II in various in vivo and in vitro models of atherosclerosis or AMI, including the therapeutic perspective of sPLA2-II inhibitors. It was concluded that sPLA2-II appears to be an important inflammatory mediator of cardiovascular disease.
. Introduction
typical inflammation marker in humans, constitute an independent risk marker for cardiovascular events both in Atherosclerosis and one its major consequences, acute apparently healthy individuals as well as in patients with myocardial infarction (AMI), are major cardiovascular established cardiovascular disease such as stable angina conditions in the Western World. Traditionally, these pectoris [1] . The beneficial effects of statins, originally conditions are considered to result from lipid abnordeveloped because of their cholesterol-lowering properties, malities, and other risk factors such as hypertension, may at least in part be related to their anti-inflammatory smoking, hyperhomocysteinemia and diabetes. However, properties [2] . Also, many of the processes ensuing in evidence is now accumulating that in addition to these, atherosclerotic vessels during the various stages of the inflammatory reactions in the atherosclerotic lesions as lesions, such as the influx and activation patterns of blood well as in the infarcted myocardium have a major impact mononuclear cells, show remarkable similarities to proon incidence and outcome of atherosclerosis and AMI. For cesses occurring in established immune or inflammatory example, a number of studies during the last decade have diseases [3] . This growing appreciation of a role for shown that plasma levels of C-reactive protein (CRP), a inflammation in atherosclerosis has even led some to speculate that this condition may result from or be enhanced by microbial infections in the vessel wall, viruses [4] . Pathological studies of the hearts of persons dying from AMI have provided compelling evidence that explains why inhibitors of PLA2 enzymes have received inflammatory reactions ensue in the ischemic myocardium considerable attention by pharmaceutical companies as starting hours after the onset of complaints. Numerous drug targets. Hydrolysis of phospholipids in membranes by studies in animals have shown that anti-inflammatory PLA2 requires binding of the enzyme to the membrane, the agents under some conditions can reduce infarction size binding of which is dependent on electrostatic (chargesubstantially in AMI [5] [6] [7] . Initial clinical studies with a charge) interactions amongst others [12] . naturally occurring complement inhibitor, C1-inhibitor, have yielded promising results [8] .
Inflammatory reactions are mediated by an array of so-called inflammatory mediators which amongst others 3 . Secretory PLA2-II (sPLA2-II) include cytokines, complement and many more. Type II secretory phospholipase A2 (sPLA2-II) constitutes one of sPLA2-II accumulates in inflammatory fluids [13] . the inflammatory mediators possibly involved in the Being an acute phase protein, plasma levels strongly pathogenesis of atherosclerosis and of AMI. A role for this increase during inflammatory diseases such as infections, enzyme in either disease is suggested by observations that septic shock and RA. However, processes such as carcinoits circulating levels are high in atherosclerosis and AMI.
genesis and atherosclerosis may also be accompanied by In addition, sPLA2-II has been shown to be deposited in increased circulating levels [14] . sPLA2-II is constitutively atherosclerotic arteries as well as on ischemic carexpressed in organs dealing with inflammatory response, diomyocytes. Here we discuss the idea that sPLA2-II such as spleen, thymus, intestines, liver and bone marrow, enhances atherosclerosis and exerts detrimental effects on but also in lung, kidney and ovary. Furthermore, many cell ischemic cardiomyocytes in infarcted myocardium, and types are able to secrete sPLA2-II such as endothelial cells, that the enzyme should be considered as an inflammatory smooth muscle cells, platelets, mast cells, neutrophils, mediator in cardiovascular disease rather than being an macrophages and hepatic cells. All these cells may contribepiphenomenon.
ute to the elevation of circulating levels during acute phase responses, as the synthesis of sPLA2-II by these cells is stimulated by proinflammatory cytokines [15, 16] . The 2 . Phospholipase A2 (PLA2) enzymes expression of the sPLA2-II gene is stimulated by factors as diverse as hypoxia, cytokines and phorbol esters [17] , and PLA2 are widely distributed enzymes that exist in many is amongst others regulated by transcription factors includisoforms, including the 14-kDa secretory phospholipase ing NF-kB, PPAR and C / EBP [18] . NF-kB is an essential A2 (sPLA2) and the 85-kDa cytosolic phospholipase A2 component of the cytokine signaling pathways inducing (cPLA2) [9] . sPLA2 comprises a small group of homolosPLA2-II expression. PPARs control the regulation of gous proteins with five to eight disulfide bridges. The genes involved in lipid metabolism in general. While the location of these disulfide bonds in the protein backbone human sPLA2-II promoter is controlled by C / EBP factors provides the basis for a classification into several sub- [18] . The activation of these transcription factors is under groups [10] .
the control of distinct signaling pathways, like PKC and sPLA2-I is known as pancreatic PLA2, since it is cAMP [18] . expressed at high levels in the pancreas, to be secreted into Interaction of sPLA2-II with cellular phospholipids the intestine where it hydrolyzes food-derived phosdepends in part on the nature of these phospholipids [16] . pholipids.
The enzyme binds with a higher affinity to phosphatatic Significant levels of sPLA2-I mRNA are also found in acid (PA) than to phosphatidylethanolamine (PE), phosspleen, lung and prostate. sPLA2-II was initially discovphatidylserine (PS) and phosphatidylcholine (PC) [15, 19] . ered in synovial fluid of patients with rheumatoid arthritis This binding specificity results from non-covalent interac-(RA) [11] , and subsequently found to be an acute phase tions of the amino acid backbone of the protein with the protein, of which circulating levels may increase more then phospholipids, interactions of which are apparently 100-fold during acute phase reaction. Whereas sPLA2-I stronger in the case of PA as compared to PE, PS and PC and -II are extracellular proteins that are secreted by cells, [19] . sPLA2-II has only a low affinity for PC as a cPLA2 is an intracellular cytoplasmic protein, of which substrate, which in part is explained by the presence of a mRNA has been found in many tissues including heart, critical valine residue, rather than a tryptophan residue, spleen, lung and kidney [10] .
which is found in PLA2 enzymes with a higher affinity for PLA2 enzymes hydrolyze phospholipids at the sn-2 PC [20] . The presence of the amphiphilic indole side chain position to generate free fatty acids and lysolipids, which is in tryptophan allows a better penetration of PLA-2 into the the rate-limiting step in the biosynthesis of eicosanoids and lipid interface of membranes [20] . A V3W mutant of platelet-activating factor (PAF) (Fig. 1) [12] . These subhuman sPLA2-II, in which this critical valine residue was stances are potent mediators of inflammation, apoptosis replaced by tryptophan, showed strong (250-fold) enand tumorigenesis [12] . This important biological activity hanced enzymatic activity for small unilamellar vesicles of leads to catalytic activity of cPLA . Ca (+) binds to the N-terminal calcium-dependent phospholipid-binding domain (CaLB) of cPLA and thereby 2 2 21 promotes translocation to membranes. sPLA is also dependent upon Ca , which binds to sPLA -IIvia, a specific calcium-loop. Also, sPLA -II can only PC, whereas wild-type human sPLA2-II hardly hydrolyzed vital cells are tightly packed together, and are not hydrothis substrate [20] .
lyzed by sPLA2-II. Under some conditions, the phosNotably, some biological effects of sPLA2-II are inpholipids of the inner and outer leaflet become rearranged dependent of its catalytic function [21] , suggesting it may leading to the presence of PS in the outer leaflet. This interact with specific receptors. Indeed the enzyme has process is known as membrane 'flip-flop'. Thus, a translobeen shown to bind to a high affinity receptor (K 57. 5 cation of negatively charged phospholipids (PS, and to a d pM) of 180 kDa, present on rabbit skeletal muscle [22] . lesser extent PE) from the inner layer of the membrane to This so-called M-type receptor mediates some of the the outer layer occurs during a membrane flip-flop [25] . In physiological effects of mammalian sPLA2-II, including contrast to that of normal membranes, the outer leaflet of vascular smooth muscle cell (SMC) contraction and cell flip-flopped membranes is easily hydrolyzed by sPLA2-II. proliferation. In addition, binding of sPLA2-II to this This affinity of sPLA2-II for flip-flopped membranes is receptor may induce internalization of sPLA2-II [23] .
explained by the presence of a number of cationic residues Also, murine sPLA2-II is a high affinity ligand for murine forming patches on the putative interfacial binding surface M-type receptor [24] . However, human sPLA2-II does not of the enzyme [26] . seem to be a physiological ligand for the human M-type sPLA2-II generates various lysophospholipids, such as receptor [24] . Thus, the function of this putative high lysoPC, lysoPE, lysoPS and lysoPA [13] . Interestingly, affinity sPLA2-II receptor is likely to be species-depenlyso-PA is a messenger acting through G protein-coupled dent.
receptors [27] , and can stimulate platelet aggregation, cell proliferation and SMC contraction [19] . sPLA2-II indeed has been described to induce signal-transduction in in-4 . Effector functions of sPLA2-II flammatory cells. For example, in combination with PAF, the enzyme induces exocytosis of human neutrophils [28] . Under normal conditions, the composition of phosNotably, the biological function of sPLA2-II in some cell pholipids in inner and outer leaflet is not similar. The outer types is independent of its catalytic function [22] . leaflet of the membrane contains mainly hydrophobic sPLA2-II not only hydrolyzes phospholipids in the cell phospholipids, whereas the inner contains anionic phosmembrane of cells, but also those in bacterial cell walls, pholipids such as PS, as well. Due to their hydrophobic leading to impaired integrity of the membranes [15] , and nature, the phospholipids in the outer leaflet of normal, providing the enzyme with bactericidal properties [29] . It has been shown that the assembly of the membrane-attack However, native LDL proved to be a poor substrate for complex of complement increases the susceptibility of the sPLA2-II, whereas after mild oxidation, which occurs in cell membrane of Gram-negative bacteria for sPLA2-II by atherosclerosis, the susceptibility of LDL to phospholipid producing sublethal alterations of the outer envelope of the hydrolysis is increased [42] . In another study it was shown bacteria [29] . sPLA2-II is also a primary bactericidal agent that sPLA2-II induced only little lipolytic modification of for Gram-positive bacteria [29] .
LDL, while a strong lipolytic activity was found for the subtype sPLA2-X [43] . Hence, likely subtle differences in composition, oxidation, and possibly other aspects, may 5 . Crosstalk between cPLA2 and sPLA2-II alter the susceptibility of LDL for sPLA2-II and other PLA2 enzymes. In mast cells sPLA2-II was found to mediate the Normal high density lipoprotein (HDL) reduces activity selective release of arachidonic acid (AA) by binding to of sPLA2-II [44] . However, in a co-culture system of cell surface receptors, followed by induction of signal human endothelial cells and SMCs, HDL from sPLA2-IItransduction events that lead to cPLA2 activation [30] . transgenic mice or human HDL treated with recombinant This possibly involves the activation of the PKC / Raf-1 / sPLA2-II, failed to protect against the formation of bio-MAPK signalling pathway [31] . Furthermore, in rat filogically active phospholipids in LDL [41] . Furthermore, it broblastic 3Y1 cells cPLA2 and its downstream 12-or has been shown that acute phase HDL containing 27% 15-lipoxygenase pathway were shown to enhance sPLA2-serum amyloid A (SAA), an acute phase protein, enhanced II gene expression. cPLA2 may also alter membrane sPLA2-II activity [44] . This interaction between HDL, susceptibility for sPLA2-II [32] . For example, in human SAA and sPLA2-II may explain the alterations in lipoproembryonic kidney cells, prior production of AA by cPLA2 tein metabolism during acute phase reactions [44] . sPLA2-in cytokine-stimulated cells destabilized the cellular mem-II may even hydrolyze the phospholipid monolayers of branes, and rendered them more susceptible to subsequent HDL [15] . Therefore, transgenic mice overexpressing hydrolysis by sPLA2-II [33] . In contrast, from a study in sPLA2-II have lower HDL levels, whereas levels of LDL S49 cells, it was concluded that cPLA2 reduces suscepare increased [45] . Furthermore, sPLA2-II caused a detibility of membranes to sPLA2 during apoptosis [34] .
crease in plasma HDL cholesterol in response to inflammacPLA2 as well as sPLA2-II have partially overlapping tory stimuli in mice, via a direct interaction on HDL functions. For example, in neutrophils stimulated with particle size and composition [46] . fMLP both cPLA2 and sPLA2-II were found to contribute to AA release [35] . Moreover, in the human keratinocyte cell line HaCaT, inhibition of both cPLA2 and sPLA2-II -II and cPLA2 tion, and triggers the formation of foam cells [15] . sPLA2-were rapidly activated upon CD16 cross-linking [37] .
II itself also activates macrophages via induction of the secretion of enzymes and cytokines [47] , while in the presence of LPS, sPLA2-II stimulates iNOS expression 6 . Interactions of sPLA2-II with lipoproteins and nitrite production in macrophages [48] . In primary cultures of rat endothelial cells and in two different rat Among the first events in atherogenesis is modification endothelial cell lines (SVAREC and RBE4), IL-1b-induced of low density lipoprotein (LDL) particles in the arterial sPLA2-II gene expression and secretion of the enzyme in a wall, and subsequent formation of aggregated and fused dose-and time-dependent manner [49] . In contrast, LPS lipid droplets that are relatively depleted in PC [38] . High treatment of cultured primary endothelial cells caused an levels of small dense LDL in plasma are associated with an increase of cPLA2 mRNA, but not of sPLA2-II mRNA increased risk for cardiovascular disease [39] . Small dense [50] . Whether sPLA2 contributes to AA release by endo-LDL particles are formed by reduction of the phospholipid thelial cells is not clear. At least in bovine aortic endothelicontent in the surface monolayer LDL, which causes an al cells, an inhibitor of sPLA2-II (CGP-43187) did not enhanced interaction with proteoglycans [39] . sPLA2-II affect AA release induced by the non-selective activator of may help to reduce the phospholipid content of LDL [39] .
heterotrimeric guanine nucleotide-binding proteins, NaF Also, 15-lipoxygenase-induced LDL oxidation was en- [51] . Furthermore, VEGF-enhanced PAF synthesis in hanced by sPLA2-II [40] . In vitro it was shown that HUVEC was mediated by sPLA2-V, but not by sPLA2-II sPLA2-II liberated polyunsaturated free fatty acids from [52] . phospholipids. These fatty acids increase the formation of In human vascular SMC, IL-1 did not affect sPLA2-II bioactive phospholipids in LDL, resulting in an enhanced mRNA levels, while it increased cPLA2-mRNA [53] . In ability to stimulate monocyte-endothelial interactions [41] . rabbit aortic vascular SMC, norepinephrine enhanced release of AA via activation of cPLA2 but not sPLA2-II Chlamydia pneumonia, HSV-1 and CMV was found to be [54] . associated with sPLA2-II expression and other signs of A main process induced by activated endothelial cells or local inflammation in human atherosclerosis [15] . macrophages is coagulation. sPLA2-II inhibits blood coagulation independent of its lipolytic action [55] . The enzyme inhibits prothrombinase, which is the enzyme complex that catalyzes the formation of thrombin from 9 . sPLA2-II in the heart prothrombin, and which consists of activated factors Xa and Va assembled onto a membrane surface in the presence
We have described the presence of sPLA2-II in infarcted of calcium [56, 57] . Whether this anti-coagulant effect is myocardium [65] suggesting the enzyme to be involved in relevant for the in vivo situation is not clear. From the inflammatory reactions ensuing in heart infarcts. This ellipsometric studies (an optical technique measuring the sPLA2-II may originate from the blood or be produced changes in surface-bound mass), it was concluded that locally by cardiomyocytes. Indeed, Northern blotting replasma sPLA2-II concentrations in inflammatory disease vealed the presence of mRNA of sPLA2-II in the rat heart will not be sufficiently elevated to inhibit coagulation [66] . Cytokines such as TNF-a stimulate transcription efficiently [58] . levels of sPLA2-II in isolated neonatal rat cardiomyocytes [67] . Interestingly, the borderzone of the infarcts in humans contained cells that had bound sPLA2-II [68] , which upon binding may sPLA2-II predict restenosis in patients undergoing coractivate complement. Indeed, in human myocardial infarconary angioplasty [61] .
tion, sPLA2-II depositions precede those of CRP [65] . Atherosclerotic plaques exhibit a series of features that Interestingly, there is evidence that CRP can regulate are similar to those of chronic inflammation [62] . In sPLA2-II activity in a substrate-concentration dependent humans sPLA2-II is present in the intima, media and fashion [69] . adventitia of the atherosclerotic wall, not only in mature The studies discussed above suggest a role for sPLA2-II lesions but also at a very early stage of atherosclerosis in the inflammatory damage ensuing in infarcted myocar- [15] . sPLA2-II was found in foam cells, calcifications dium. However, from a study in hearts from wild-type and sites, areas of cell necrosis and in the extracellular matrix sPLA2-II deficient mice it was concluded that sPLA2-II [62] . In the abdominal human aorta, sPLA2-II was present does not play a prominent role in the development of in all advanced atherosclerotic lesions, but only in some irreversible cell damage in the ischemic-reperfused murine preatheromas and early lesions of atherosclerosis [63] . In myocardium [70] . Notably, in this study the role of contrast, in the thoracic aorta, sPLA2-II was found at a sPLA2-II was not analyzed during acute phase reactions, similar frequency in all stages of atherosclerotic lesions, in since Langendorf perfusion of isolated hearts was used. As all three layers of the vessel wall [63] . In another study of we did not find sPLA2-II depositions in human myocardial human carotid arteries, sPLA2-II was found throughout the infarction until at least 6-12 h after the onset of symptoms, media in atherosclerotic but also in normal artery specii.e. at which time blood levels of sPLA2-II in patients with mens [64] . In contrast, in another study, sPLA2-II did not AMI start to increase [65] , acute phase concentrations of stain normal human arteries without thickened intima [62] .
sPLA2-II are likely to be required to mediate inflammatory The presence of sPLA2-II in atherosclerotic lesions is not damage in the heart. Moreover, mouse blood hardly unique for humans. The enzyme was also present in contains CRP, and hence CRP-dependent damage induced atherosclerotic lesions of transgenic mice overexpressing by sPLA2-II may have been missed in the Langendorf sPLA2-II [45] . Interestingly, the presence of DNA of perfusion model.
0. Studies with sPLA2-II inhibitors
In atherosclerosis, sPLA2-II not only plays a role in In the placenta, sPLA2-II specific antisense oligonucleomacrophage activation and foam cell formation [15, 47] , tides A and B inhibited the expression and activity of but it also hydrolyzes LDL [39] and HDL [15] , resulting in sPLA2-II [71] . Another potent inhibitor is LY315920 ([ [3- increase numbers of pro-atherogenic small LDL particles, (aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-and an impaired function of anti-atherogenic HDL. Alyl]oxy]acetate), a pharmacological drug that functions as a though sPLA2-II depositions have been found locally in selective, stoichiometric inhibitor of the catalytic activity atherosclerotic lesions [62, 63] , and clinical studies have of sPLA2-II. LY315920 inhibited sPLA2-II serum activity revealed a correlation between sPLA2-II and vascular after intravenous or oral administration to transgenic mice complications [39, 60] , until now the role of sPLA2-II in expressing the human sPLA2-II [72] . Other novel sPLA2-the induction of local complications of atherosclerotic II inhibitors, petrosaspongiolide M (isolated from the plaques themselves or subsequent vascular complications Caledonian marine sponge Petrosaspongia nigra), and has not been clarified. Also, the relevance of the anticacospongionolide B (isolated from the sponge Fascioscoagulant function of sPLA2-II remains to be established pongia cavernosa), had anti-inflammatory properties in [56] . With regard to the latter, one may speculate that the mice and rats with respect to arthritis and post-inflammaenzyme induces prolonged bleeding in a complicated tory edema [73, 74] . Unfortunately, no studies with these atherosclerotic plaque, which can result in vascular cominhibitors have been performed in animal models for plications. Also, the potential antibactericidal effects of myocardial infarction. So it remains to be established sPLA2-II within atherosclerotic plaques, is not well estabwhether sPLA2-II inhibitors are useful in the treatment of lished [15, 29] . AMI.
With respect to putative therapeutical options in atheroSome drugs developed because of other biological sclerosis, it has been shown that sPLA2-II activity in properties, also appeared to inhibit sPLA2-II activity or patients with hypercholesterolemia who receive statins, is sPLA2-II-induced phenomena. Alminoprofen, a NSAID (a inhibited [2] . Also, aspirin is able to reduce sPLA2-II member of the phenylpropionic acid class of drugs), and levels [75, 76] . Yet, at the moment it can only be speculated aspirin inhibit sPLA2-II activity [75, 76] , as does heparin that the beneficial effects of either drug is due to their [77] . Another NSAID, indomethacin, inhibits sPLA2-ineffect on circulating sPLA2-II. Yet, except for a potential duced aggregation of platelets [75] . Chemically modified anti-coagulant effect, all the evidence to date points to a tetracyclines, devoid of antimicrobial properties, not only detrimental role for sPLA2-II in the development of inhibit sPLA2-II but also some matrix metalloproteinases, atherosclerotic lesions. Thus, although the role of sPLA2-II that play an important role in the process of atherosclerosis in atherosclerosis remains a matter of speculation, studies [78] . Furthermore, in patients with hypercholesterolemia, with specific sPLA2-II inhibitors in animal models for both simvastatin and atorvastatin caused a reduction in atherosclerosis seem to be warranted. Also, in AMI the sPLA2-II [2] . Whether the beneficial effects on carfunction of sPLA2-II seems to be detrimental in that it diovascular disease of the drugs discussed in this section promotes inflammation. Hence, for the treatment of AMI, are due to their effects on sPLA2-II remains to be specific inhibitors of the enzyme also constitute an attracestablished yet.
tive option. The time-window for the start of therapy with sPLA2-II inhibitors in patients is likely to be 6-24 h after the onset of complaints, as blood levels start to increase in 1 1. Discussion this period, which is accompanied with deposition of the enzyme in the ischemic myocardium. To our knowledge, Inflammation plays an important role in both atherobinding of sPLA2-II to jeopardized cardiomyocytes seems sclerosis and acute myocardial infarction (AMI), although to be among the first events in the processes that ultimately via different mechanisms. Inflammation in atherosclerosis lead to the death of these cells [65] . We speculate that a likely contributes to recruitment of inflammatory cells in major event in these processes is the binding of CRP, the lesions and the formation of foam cells, and also to the which is facilitated by the effects of sPLA2-II on memformation of unstable plaques or plaque ruptures, which brane phospholipids in the outer leaflet of injured cells. are the main processes that elicit (cardio)vascular events.
Complement and neutrophils are also among the inflammaIn AMI, local inflammatory reactions in the ischemic tory mediators triggered by sPLA2-II and CRP in the myocardium contribute to myocardial damage and infarcischemic myocardium [1, 65] . To what extent sPLA2-II tion size and play a role in tissue remodelling [65] .
locally produced by cardiomyocytes contribute to the Various inflammatory mediators have been identified to inflammation in the heart is not yet clear, although the play a role in both atherosclerosis and AMI, including time-relationship between increasing plasma levels and the cytokines, adhesion molecules, complement and acute deposition in the heart suggest most of the enzyme is phase proteins. Among the latter is type-II secretory derived from the blood [70] . Nevertheless, current underphospholipase A2 (sPLA2-II) [1] . All current evidence standing of the role of sPLA2-II in patients with AMI thus far supports the use of specific sPLA2-II inhibitors in these (Fig. 2) . Although the local effect of sPLA2-II in atheropatients.
sclerosis has to be studied in more detail, the results of the In conclusion sPLA2-II plays an important studies discussed above make it worthwhile to start in vivo pathophysiological role in both atherosclerosis and AMI animal studies with sPLA2-II inhibitors with respect to Fig. 2 . Overview of the role of sPLA -II in atherosclerosis and in post-AMI damage to cardiomyocytes. In blood vessels sPLA -II promotes 2 2 atherosclerosis. sPLA has been found in atherosclerotic plaques where it induces (small dense) LDL increase, HDL decrease and it triggers macrophages eventually also in humans.
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